Novartis's Tasigna receives first approval in Switzerland
Switzerland is the first country to approve the drug, which offers a cancer therapy for patients with a form of the life-threatening blood cancer chronic myeloid leukemia who are resist...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
